Timothy Mark Dyer - 18 Mar 2026 Form 3 Insider Report for Addex Therapeutics Ltd. (ADXN)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: ADXN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 11:07:06 UTC
Source filing: View source filing
Reporting owner signature: /s/ Timothy Mark Dyer

Key filing fact

Timothy Mark Dyer filed Form 3 for Addex Therapeutics Ltd. (ADXN) on 18 Mar 2026.

Key facts

This page summarizes Timothy Mark Dyer's Form 3 filing for Addex Therapeutics Ltd. (ADXN).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 11:07.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001830908 Primary reporting owner

Dyer Timothy Mark

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: CHEMIN DES MINES 9, GENEVA, SWITZERLAND
Signature: /s/ Timothy Mark Dyer
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADXN holding

Common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 16,848,979
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADXN holding Derivative

Stock-Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 3,369,796
Exercise price: $0.0640
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents 16,848,979 shares of Common Stock listed on SIX Swiss Exchange.

Footnote F2

The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants the right to purchase one ADXN share listed on SIX Swiss Exchange.

Footnote F3

The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.